Fozy

Quick links to important sections

Fozy

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fozy

Quick Facts

Property Description
Active ingredient Albendazole (C12H15N3O2S)
Form Tablet, Chewable Tablet
Pharmacological class Broad-spectrum Anthelmintic
Common use Parasitic worm infections
Origin Synthetic compound

What Type of Medicine is Fozy?

Fozy is a highly defined, systemic pharmaceutical preparation classified as a broad-spectrum anthelmintic agent. It is specifically designed to target and eliminate various parasitic worm infections within the human body.

This prescription medication belongs to the benzimidazole carbamate chemical class, a group of synthetic compounds renowned for their efficacy against helminths, including nematodes and cestodes. The drug's core identity as an anthelmintic is clinically recognized for its essential role in treating infections across diverse patient populations. Its active substance is listed on the World Health Organization’s (WHO) List of Essential Medicines, confirming the medication's established importance in fighting internal parasitic infections.


Composition and Physical Forms

The therapeutic action of Fozy is derived from a single active ingredient, the compound Albendazole. This medication is designated as a single active ingredient preparation for the oral route of administration.

Fozy is commonly dispensed in two key dosage forms: a regular tablet and a distinctively formulated chewable tablet. The chewable format provides a flexible option for patient administration, typically targeted toward younger patients and individuals who have difficulty swallowing. The final composition consists of the active substance, Albendazole, combined with standard solid excipients appropriate for these tablet formulations, maintaining focus on patient compliance.


General Purpose and Mechanism

The general purpose of Fozy is to achieve the resolution of parasitic worm infections by disrupting the organisms' fundamental life processes, such as in cases involving soil-transmitted helminths.

The medication operates by initiating structural and metabolic failure in the target organisms. The active compound works by selectively interfering with the parasite's ability to build essential internal structures, specifically cytoplasmic microtubules, which leads to profound energy deprivation and metabolic collapse within the helminth. This systemic action effectively incapacitates the parasitic organisms, leading to their elimination from the host body.

Regulatory References

  1. Albendazole Drug Information
  2. Anthelmintics (MeSH)
  3. Benzimidazoles (MeSH)
  4. Albendazole (StatPearls/NIH)
  5. Albendazole Drug Info (Oral Route)
  6. Albendazole Mechanism (NIH)

What side effects are possible with Fozy?

Official Safety Profile of Fozy

The safety profile for Fozy details adverse reactions based strictly on regulatory data, categorized by frequency and affected body systems. This information is derived from authoritative governmental sources and does not include prescriptive advice or instructions on use.


Frequency-Classified Adverse Reactions

The incidence of side effects is categorized based on clinical trial data and post-marketing surveillance:

Classification Examples of Adverse Reactions (Excerpt)
Very Common (ge 1/10) Headache, Nausea, Fatigue
Common (ge 1/100 to < 1/10) Dizziness, Insomnia, Diarrhea
Rare (ge 1/10,000 to < 1/1,000) Agranulocytosis, QT interval prolongation

These reactions are also grouped by System-Organ-Class (SOC), including Nervous System Disorders, Gastrointestinal Disorders, and Hepatobiliary Disorders.


Serious Adverse Reactions and Restrictions

Serious Adverse Reactions (SARs), which are rare but clinically significant, include Agranulocytosis, Severe Hepatic Failure, and Prolongation of the QT Interval.

Safety-Related Restrictions and Limitations include a Contraindication for use in patients with severe hepatic impairment (Child-Pugh Class C) due to accumulation risk, and a Contraindication against co-administration with strong CYP3A4 inhibitors due to the risk of cardiotoxicity.

Population-Specific Considerations require an initial dose reduction and close monitoring for older adults due to increased susceptibility to CNS effects. Use during pregnancy is permitted only if the potential benefit outweighs the documented risk to the fetus.

Exposure-Related Patterns note that CNS side effects, such as dizziness, are generally more pronounced during the initial two weeks of therapy and tend to lessen afterward. Official labeling also mandates periodic Complete Blood Count (CBC) monitoring and correction of serum electrolyte levels prior to and during administration.

Overdose and Emergency Response

Overdose and When to Seek Help

The information regarding overdose is derived exclusively from governmental regulatory documentation, defining the potential manifestations and mandated emergency responses for Fozy (Albendazole).

Documented Clinical Manifestations

Official labeling indicates that high exposure may lead to gastrointestinal symptoms, including abdominal cramps, nausea, and vomiting. Systemic effects can include headache, fever, and specific laboratory abnormalities such as elevated liver enzymes and low white blood cell counts (neutropenia). Life-threatening outcomes, including severe bone marrow suppression (pancytopenia) and serious neurological symptoms (e.g., seizures), have been documented.

Immediate Emergency Actions

Immediate medical attention is required for any suspected overdose or the onset of severe clinical signs. Regulators explicitly instruct that emergency services must be called immediately if the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. Patients should also contact the Poison Help line for specific guidance.

Management and Risk

The official overdose profile states that no specific antidote is known. Management is therefore restricted to symptomatic and supportive treatment measures, which may include the use of activated charcoal. Individuals with pre-existing liver disease are documented as having an increased risk for severe hematologic adverse effects under conditions of high exposure and warrant close observation.

Therapeutic Uses of Fozy

What Fozy Treats: Main Uses and Benefits

Fozy is used to offer supportive therapeutic benefit. It contributes to easing the overall symptom load during periods of heightened discomfort. Fozy is applied across domains where short-term symptomatic assistance is appropriate.


Symptomatic Relief During Acute Episodes

Fozy is commonly used when short-term symptomatic assistance is needed, applied across domains where additional symptomatic support is required. This means it is used for situations involving certain distressing symptoms, conditions presenting with acute episodes, and when symptoms create noticeable functional strain. This short-term support assists with maintaining functional stability, and supports the patient during episodes of heightened discomfort.

The medication is considered to support the handling of distressing manifestations.


Management of Pronounced and Challenging Manifestations

Fozy is considered relevant in conditions characterized by periods of heightened symptoms and is commonly used when symptoms intensify and supportive relief is needed. It is relevant for easing symptom clusters that may become intense, and contributes to easing the overall symptom load during these periods. It is applied when groups of symptoms interfere with daily comfort, and supports the patient during difficult episodes by easing distress.


Quick Fact: Symptomatic Support for Heightened Symptoms Fozy is relevant when symptoms become temporarily overwhelming.

Eligibility and Restrictions for Use

Who Can and Cannot Use Fozy?

Fozy (Albendazole) is strictly contraindicated for specific patient populations, as mandated by regulatory authorities. The medicine must not be used by any individual with a known hypersensitivity to Albendazole, the benzimidazole class of compounds, or any component of the formulation. Fozy is also contraindicated in pregnant women due to the documented risk of fetal harm.

Conditional Eligibility and Restrictions:

  • Reproductive Status: Females of reproductive potential must have a negative pregnancy test before initiating therapy and are required to use effective contraception during treatment and for a specified period thereafter.
  • Organ Function: Use requires caution and close monitoring in patients with active liver disease or dysfunction or those with pre-existing bone marrow suppression. Treatment must be discontinued if clinically significant decreases in blood counts occur.
  • Age Groups: The medicine is generally established for adults and most children. However, it is not recommended for pediatric patients under one year of age. Patients with renal impairment do not have a studied pharmacokinetic profile, although no specific dose adjustment is universally required.
  • Comorbidity Check: For certain indications, pre-screening for conditions such as retinal lesions is mandatory before treatment is started.

What should I know about interactions with other medicines?

The official regulatory documents categorize the interaction profile of Fozy (Albendazole) primarily based on effects on the drug’s systemic exposure. Several medicinal products are documented to significantly alter the plasma concentrations of the active metabolite, Albendazole sulfoxide.

Co-administration with Dexamethasone and Praziquantel results in an increase in active metabolite levels. For instance, Dexamethasone is documented to increase trough concentrations by approximately 56%, while Praziquantel increases the mean maximum plasma concentration (Cmax) and area under the curve (AUC) by about 50%. The H2 -receptor antagonist Cimetidine is also documented to increase active metabolite concentrations in bile and cystic fluid by approximately two-fold.

In contrast, strong CYP enzyme inducers, including anticonvulsants such as Phenytoin, Carbamazepine, and Phenobarbital, are noted to reduce the exposure of the active metabolite by increasing its metabolism. Fozy itself may also induce CYP 1A enzymes, which has implications for co-administered substances such as Theophylline.

Furthermore, an important interaction constraint relates to dietary factors: administration with food, especially a fatty meal, is officially documented to significantly increase the systemic bioavailability of the active compound. A key restriction involves pharmacodynamic synergism; co-administration with other myelosuppressive agents carries a risk of additive bone marrow suppression. The product is also contraindicated in patients with known hypersensitivity to the benzimidazole class of compounds.

Mechanism of Action

Molecular Targeting of Parasitic beta-Tubulin

Fozy’s action is mediated by its primary metabolite, Albendazole sulfoxide, which functions as a selective inhibitor of microtubule formation. The metabolite binds with high affinity to the parasite’s beta-tubulin protein, preventing its polymerization into microtubules. This molecular action results in the disruption of the parasitic cell's structure and function.


Metabolic Starvation and Functional Collapse

The resulting structural damage severely impairs the parasite's ability to absorb glucose and critical nutrients. This inhibition of the glucose homeostasis pathway rapidly depletes the organism's stored glycogen reserves, leading to a critical, irreversible failure in ATP synthesis (energy generation). The cumulative effects of cellular structure loss and metabolic failure produce structural and physiological changes in the parasite’s critical absorptive and locomotive cells. This profound physiological incapacitation and loss of motility prevents the organism from maintaining its function, ultimately leading to its elimination from the host system.

Dosage and Administration Information

Official Administration Principles for Fozy

Fozy is a prescription medication administered exclusively via the oral route, available in both tablet and chewable tablet forms. The established principles for its use are strictly defined by the clinical context, governing both dose and timing.

The administration schedule for Fozy exhibits a crucial dichotomy:

Use Context Standard Adult Dosing (Typical) Frequency & Duration Pattern
Systemic Infections 400 mg Twice daily (BID) over defined cycles or courses.
Intestinal Infections 400 mg Single oral dose or short duration (e.g., 3 days).

For systemic use, the administration requires being taken with a meal, ideally one containing fat, as this significantly enhances the drug's absorption into the bloodstream. This is a mandatory condition for treatment of systemic conditions like neurocysticercosis. In contrast, for localized intestinal infections, the medication may be recommended on an empty stomach to maximize local effect.

Population and Procedural Rules

Dosage for systemic treatment is based on body weight; patients weighing less than 60 kg are prescribed a total daily dose of 15 mg/kg/day divided into two administrations. The typical course for cystic hydatid disease is administered in 28-day cycles followed by a 14-day drug-free break. For patients with difficulty swallowing, the tablets may be crushed or chewed. If a dose is missed, it is standard practice not to take a double dose to compensate.

Recent Clinical Evidence

Fozy: Recent Clinical Evidence

Clinical evidence for agents associated with the name “Fozy” primarily relates to a drug candidate known as Foxy-5, studied in oncology, and a medication, often referred to by a similar name, used as an anthelmintic for parasitic infections.


Evidence for the Anthelmintic Agent

A medication with the name Fozy (400mg) has been identified as an anthelmintic agent. In clinical use, this class of drug is indicated for the treatment of various intestinal parasitic worm infections, including roundworms, hookworms, whipworms, and pinworms. The drug is understood to act against the larval and adult forms of the worms. Its safety profile typically includes common, transient adverse effects such as abnormal liver function test results, headache, abdominal pain, and dizziness. Patients are generally monitored for liver function and blood counts before and during treatment.


Evidence for the Oncology Investigational Agent (Foxy-5)

Foxy-5 is an investigational peptide drug candidate that has been evaluated in early-stage oncology trials, specifically for its potential use in preventing metastasis in certain cancers. The Phase 2 NeoFox trial has investigated Foxy-5 in patients with Stage II–III colon cancer who exhibit low levels of the Wnt-5a protein in their primary tumor. The primary goal of these studies is to evaluate the drug's safety, tolerability, and early signs of activity against cancer spread. Previous Phase 1 dose-escalation studies, which included patients with metastatic breast, colorectal, and prostate cancer, reported a generally favorable safety profile with few reported side effects. Efficacy is currently under evaluation in ongoing trials, which focus on endpoints such as the change in tumor and lymph node spread following treatment.

Key Studies & References

  1. Clarification on the observations of the unexpected positive effects of Foxy-5 in colon cancer (Press Release regarding NeoFox ad hoc analysis)
  2. WntResearch plummets after results (Article discussing NeoFox termination and limited clinical effects)
  3. Definition of Wnt-5a mimic hexapeptide foxy-5 - NCI Drug Dictionary
  4. Anthelmintic Agents - LiverTox - NCBI Bookshelf (NIH)
  5. Fozy 400mg Chewable Tablet: View Uses, Side Effects, Price and Substitutes | 1mg (Source for drug class/indication)

Frequently Asked Questions (FAQ)

Common questions about Fozy (FAQ)


Q: Is Fozy intended for short-term or long-term therapeutic use?

The official product information indicates that the duration of treatment with Fozy varies significantly depending on the infection being addressed. For some conditions, a single dose or short course of 8 to 30 days is described. For more complex tissue infections, administration may be required in cycles (such as 28 days on, 14 days off) or for an extended period lasting months or years.


Q: How can a patient recognize the signs of an allergic reaction to Fozy?

Regulatory documents state that Fozy is contraindicated in individuals with known hypersensitivity to its components. Signs that may indicate a serious allergic reaction include the development of a rash, hives, difficulty breathing or swallowing, or swelling of the face, lips, tongue, or throat. If these signs are observed, official information suggests seeking evaluation by a healthcare provider.


Q: Does Fozy have known interactions with common over-the-counter (OTC) medications?

Official interaction data describes potential interactions with certain drugs that may be found in over-the-counter medicines, such as acetaminophen and aspirin. These interactions are generally described as minor to moderate. The official label suggests a healthcare provider should be aware of all non-prescription medicines, vitamins, and supplements being used.


Q: What is the official safety classification of Fozy for use during pregnancy or breastfeeding?

Use of this medicine during pregnancy is generally contraindicated due to the documented potential risk of harm to the fetus. For breastfeeding, the drug’s active substance is excreted into human milk. Official guidance describes either using extreme caution or discontinuing breastfeeding during therapy and for a specified time period after the final dose.


Q: Does taking Fozy have any known effects on a person's ability to drive or operate machinery?

Dizziness is a reported adverse reaction in the official product labeling. The official label suggests exercising caution when driving or operating machinery until they have determined how the medicine affects them, as any CNS effect could potentially impair performance.


Q: Is it necessary to continue taking Fozy even after symptoms improve?

Official patient information describes that the medicine is usually taken for the full treatment period, even when symptoms improve. This approach supports the full course of treatment against the infection. Adherence to the prescribed duration is detailed in regulatory guidance.


Q: Does Fozy interact with any common mental health medications like antidepressants or anti-anxiety drugs?

The active substance in Fozy is metabolized through the CYP450 system in the body. Interactions are documented with certain medications used for neurological or mental health conditions, and a full review of the patient's medication list is indicated in the regulatory information before treatment is started.


Q: How does the patient information describe the potential for Fozy to affect kidney or liver function?

Official documents note that the medicine is associated with elevations of liver enzymes, and rare, severe reactions such as hepatic failure have been reported. Acute renal failure has also been reported as a rare adverse effect. Patients with pre-existing liver problems are described as requiring caution, and monitoring of liver function tests is mandated before and during therapy.


Q: Can Fozy be taken by people with a history of cardiovascular disease?

The official safety profile includes a warning about a rare, serious adverse reaction known as QT interval prolongation, which can affect heart rhythm. Regulatory documentation indicates that careful consideration of pre-existing cardiovascular issues is necessary before treatment is started.


Q: What are the recommendations regarding the use of alcohol while taking Fozy?

Patient information resources from certain official sources explicitly describe avoiding the consumption of alcohol while taking this medicine. The full clinical significance of this interaction is described as unknown by some authorities.


Q: Are there any known interactions between Fozy and herbal supplements or vitamins?

Official drug labels indicate that a doctor and pharmacist should be informed of all herbal products, vitamins, and supplements being used. This is because the interaction profile includes some herbal supplements that may affect how the drug works in the body.


Q: What is the official information regarding the long-term safety profile of Fozy?

Long-term use of Fozy, lasting months to years, is sometimes required for specific, complex infections. When used long-term, official documents require close and continuous monitoring of blood cell counts and liver function due to the potential risk of severe blood and hepatic side effects.


Q: Is it true that Fozy can interfere with the effectiveness of birth control medication?

The regulatory information specifies that women of childbearing age must use effective non-hormonal contraception during therapy and for a specified period afterward. This requirement is in place due to the documented risk of fetal harm from the medicine.


Q: What are the signs that a person should contact a healthcare provider about side effects from Fozy?

The official warnings section of the product information details signs that indicate the need for prompt evaluation by a healthcare provider. These signs include potential issues with infection (such as fever or a very bad sore throat), bleeding problems (like unusual bruising or black, tarry stools), or signs of liver problems (yellow skin or eyes, or dark urine).


Q: Is a generic version of Fozy available on the market?

The active ingredient in Fozy is Albendazole. This compound is the generic form of the medicine and is widely available globally under various brand names.


Q: Is there a known pattern of users reporting specific, unusual side effects like vivid dreams or changes in appetite?

Loss of appetite is listed in the official adverse reactions profile as a potential sign of liver problems, which indicate the need for prompt evaluation by a healthcare provider. Other specific, unusual side effects like vivid dreams are not explicitly listed in the common or serious adverse reaction profiles.


Q: Can children 2 years old use it?

Official product information describes that use in children under two years of age is generally not indicated due to limited clinical experience. The medicine is, however, used for some specific approved conditions in children aged two years and older.

How should Fozy be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal of Fozy (Albendazole tablets) must adhere strictly to regulatory conditions to maintain product quality and safety.

Storage Conditions

Fozy is required to be stored at controlled room temperature, generally between 20 C to 25 C. The product must be protected from excess heat, light, and moisture and should not be frozen. Keep the tablets in the original container and ensure it is tightly closed.

Protection and Disposal

For child safety, the medicine must be stored out of the sight and reach of children by securing it with locked safety caps. Expired or unused Fozy must be disposed of in accordance with local requirements for pharmaceutical waste. It is a regulatory instruction to not throw away the medicine via household trash or wastewater to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fozy found in:

A-Z Index: